# Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Canonical URL: https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-showing-sustained-glucocorticoid-dose-reductions-while-maintaining-androgen-control-in-adults-with-classic-congenital-adrenal-hyperplasia
Ticker: NBIX
Company: Neurocrine Biosciences
Source: Neurocrine Biosciences
Published: 2026-04-22 20:05 EST
Original Source URL: https://neurocrine.gcs-web.com
## Summary

Approximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic‑range glucocorticoid dosing at two years 75% of patients originally taking dexamethasone transitioned off this treatment, enabling a more physiologic glucocorticoid regimen without compromising androgen

## Article Body
Approximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic‑range glucocorticoid dosing at two years 75% of patients originally taking dexamethasone transitioned off this treatment, enabling a more physiologic glucocorticoid regimen without compromising androgen
## Recent Company News
- 2026-06-03 12:30 EST — [Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-new-two-year-crenessityr-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026) — Source: Neurocrine Biosciences
- 2026-05-26 20:01 EST — [Neurocrine Biosciences to Present at Upcoming Investor Conferences in June](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-june) — Source: Neurocrine Biosciences
- 2026-05-18 20:05 EST — [Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-real-world-data-highlighting-functional-impact-of-mild-tardive-dyskinesia-severity-and-improvement-with-ingrezzar-valbenazine-capsules) — Source: Neurocrine Biosciences
- 2026-05-18 12:46 EST — [Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-completes-acquisition-of-soleno-therapeutics) — Source: Neurocrine Biosciences
- 2026-05-06 12:30 EST — [Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-publication-of-expert-recommendations-for-glucocorticoid-dose-reduction-after-initiating-crenessityr-crinecerfont-for-the-treatment-of-classic-congenital-adrenal-hyperplasia) — Source: Neurocrine Biosciences
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)